BR112017018192A2 - composto ou um sal farmaceuticamente aceitável do mesmo, e, composição farmacêutica. - Google Patents

composto ou um sal farmaceuticamente aceitável do mesmo, e, composição farmacêutica.

Info

Publication number
BR112017018192A2
BR112017018192A2 BR112017018192-4A BR112017018192A BR112017018192A2 BR 112017018192 A2 BR112017018192 A2 BR 112017018192A2 BR 112017018192 A BR112017018192 A BR 112017018192A BR 112017018192 A2 BR112017018192 A2 BR 112017018192A2
Authority
BR
Brazil
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
pharmaceutical composition
chemical formula
Prior art date
Application number
BR112017018192-4A
Other languages
English (en)
Other versions
BR112017018192B1 (pt
Inventor
Eung Park Chun
Koo Jang Young
Je Shin Yong
Yeon Kim Ji
Mo Ham Seung
Gil Kim Yong
Kyung Min Hye
Bong Cha Soo
Jun Jung Hyo
Young Lee Ju
Nam Han Seung
Yong Chung Jin
Ju Choi Eun
Mi Joung Chan
Sil Park Jong
Ryune Cho Nahm
Won Lee Ji
Young Maeng Cheol
Ju Ryu Eun
Original Assignee
Sk Biopharmaceuticals Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sk Biopharmaceuticals Co., Ltd. filed Critical Sk Biopharmaceuticals Co., Ltd.
Publication of BR112017018192A2 publication Critical patent/BR112017018192A2/pt
Publication of BR112017018192B1 publication Critical patent/BR112017018192B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

a presente descrição proporciona um composto da fórmula química (1) ou um sal farmaceuticamente aceitável do mesmo, e uma composição farmacêutica compreendendo o mesmo. o composto da fórmula química (1) ou sal farmaceuticamente aceitável do mesmo atua como um modulador alostérico positivo do receptor de glutamato metabotrópico de subtipo 5 (mglur5), sendo assim útil na prevenção ou no tratamento de distúrbio mediado pela disfunção de glutamato e mglur5.
BR112017018192-4A 2015-02-26 2016-02-25 Composto ou um sal farmaceuticamente aceitável do mesmo, e,composição farmacêutica BR112017018192B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20150027395 2015-02-26
KR10-2015-0027395 2015-02-26
PCT/KR2016/001887 WO2016137260A1 (en) 2015-02-26 2016-02-25 Imidazopyrimidine and imidazotriazine derivative, and pharmaceutical composition comprising the same

Publications (2)

Publication Number Publication Date
BR112017018192A2 true BR112017018192A2 (pt) 2018-04-17
BR112017018192B1 BR112017018192B1 (pt) 2023-11-21

Family

ID=56788906

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017018192-4A BR112017018192B1 (pt) 2015-02-26 2016-02-25 Composto ou um sal farmaceuticamente aceitável do mesmo, e,composição farmacêutica

Country Status (22)

Country Link
US (5) US9745310B2 (pt)
EP (2) EP3262047B1 (pt)
JP (1) JP6692367B2 (pt)
KR (1) KR102577178B1 (pt)
CN (1) CN107635994B (pt)
AR (1) AR103769A1 (pt)
AU (1) AU2016224227B2 (pt)
BR (1) BR112017018192B1 (pt)
CA (1) CA2976422C (pt)
CL (1) CL2017002163A1 (pt)
DK (2) DK3262047T3 (pt)
ES (2) ES2854288T3 (pt)
FI (1) FI3842436T3 (pt)
HK (1) HK1244275A1 (pt)
IL (1) IL254070B (pt)
MX (1) MX2017010630A (pt)
PL (2) PL3842436T3 (pt)
PT (2) PT3262047T (pt)
RU (1) RU2710556C2 (pt)
TW (1) TWI713497B (pt)
WO (1) WO2016137260A1 (pt)
ZA (1) ZA201705333B (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220086607A (ko) * 2019-10-21 2022-06-23 에스케이바이오팜 주식회사 발달 장애의 예방, 경감 또는 치료를 위한 이미다조피리미딘 또는 이미다조트리아진 화합물의 용도
JP2022553323A (ja) * 2019-10-21 2022-12-22 エスケー バイオファーマスティカルズ カンパニー リミテッド 認知障害の予防、軽減又は治療、又は認知機能の改善のためのイミダゾピリミジン又はイミダゾトリアジン化合物の使用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4056589B2 (ja) * 1996-07-19 2008-03-05 武田薬品工業株式会社 複素環化合物、その製造法および用途
US6596731B2 (en) * 2001-03-27 2003-07-22 Hoffmann-La Roche Inc. Substituted imidazo[1,2-A] pyridine derivatives
US7329662B2 (en) * 2003-10-03 2008-02-12 Hoffmann-La Roche Inc. Pyrazolo-pyridine
AU2005219791B2 (en) * 2004-03-05 2011-06-09 Msd K.K. Diaryl-substituted five-membered heterocycle derivative
ATE463495T1 (de) * 2005-09-27 2010-04-15 Hoffmann La Roche Oxadiazolylpyrazolopyrimidine als mglur2- antagonisten
ES2689444T3 (es) * 2006-11-22 2018-11-14 Incyte Holdings Corporation Imidazotriazinas e imidazopirimidinas como inhibidores de la quinasa
WO2008151184A1 (en) 2007-06-03 2008-12-11 Vanderbilt University Benzamide mglur5 positive allosteric modulators and methods of making and using same
AU2010239253A1 (en) 2009-04-23 2011-11-24 Merck Sharp & Dohme Corp. 2-alkyl piperidine mGluR5 receptor modulators
AR078172A1 (es) * 2009-09-15 2011-10-19 Sanofi Aventis Fenoximetil dihidro oxazolopirimidinonas sustituidas y uso de las mismas como moduladores de receptores metabotropicos de mglur
WO2011035324A1 (en) 2009-09-21 2011-03-24 Vanderbilt University O-benzyl nicotinamide analogs as mglur5 positive allosteric modulators
EP2519521B1 (en) * 2009-12-29 2013-11-20 Eli Lilly and Company Tetrahydrotriazolopyridine compounds as selective mglu5 receptor potentiators useful for the treatment of schizophrenia
US8785481B2 (en) * 2010-09-29 2014-07-22 Merck Sharp & Dohme Corp. Ether benzotriazole derivatives
JP2013544891A (ja) 2010-12-08 2013-12-19 ヴァンダービルト ユニバーシティー ｍＧＬＵＲ５受容体のアロステリック調節剤としての二環式ピラゾール化合物
US8592422B2 (en) * 2010-12-17 2013-11-26 Vanderbilt University Bicyclic triazole and pyrazole lactams as allosteric modulators of mGluR5 receptors
EP2681218A1 (en) * 2011-02-23 2014-01-08 Pfizer Inc IMIDAZO[5,1-f][1,2,4]TRIAZINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
CA2830220A1 (en) * 2011-03-15 2012-09-20 Vanderbilt University Substituted imidazopyrimidin-5(6h)-ones as allosteric modulators of mglur5 receptors
ES2790358T3 (es) * 2011-12-28 2020-10-27 Global Blood Therapeutics Inc Compuestos de heteroaril aldehído sustituido y métodos para su uso en el aumento de la oxigenación tisular
US9422279B2 (en) * 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
GB201321736D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents

Also Published As

Publication number Publication date
US20210300933A1 (en) 2021-09-30
EP3262047A4 (en) 2018-08-01
CA2976422C (en) 2023-09-26
DK3842436T3 (da) 2024-02-05
HK1244275A1 (zh) 2018-08-03
EP3842436A1 (en) 2021-06-30
IL254070A0 (en) 2017-10-31
PT3262047T (pt) 2021-02-25
US11046702B2 (en) 2021-06-29
CN107635994B (zh) 2019-11-05
PL3842436T3 (pl) 2024-03-04
BR112017018192B1 (pt) 2023-11-21
TWI713497B (zh) 2020-12-21
ES2854288T3 (es) 2021-09-21
RU2017131514A3 (pt) 2019-05-31
EP3842436B1 (en) 2023-11-08
ZA201705333B (en) 2019-07-31
PT3842436T (pt) 2023-12-28
JP2018506561A (ja) 2018-03-08
AU2016224227A1 (en) 2017-08-31
TW201639848A (zh) 2016-11-16
DK3262047T3 (da) 2021-03-01
US20200277298A1 (en) 2020-09-03
CA2976422A1 (en) 2016-09-01
US20170349597A1 (en) 2017-12-07
EP3262047A1 (en) 2018-01-03
US10100057B2 (en) 2018-10-16
RU2017131514A (ru) 2019-03-26
AR103769A1 (es) 2017-05-31
US9745310B2 (en) 2017-08-29
RU2710556C2 (ru) 2019-12-27
PL3262047T3 (pl) 2021-05-31
WO2016137260A1 (en) 2016-09-01
CL2017002163A1 (es) 2018-06-22
AU2016224227B2 (en) 2020-01-16
FI3842436T3 (fi) 2024-01-24
ES2964324T3 (es) 2024-04-05
EP3262047B1 (en) 2021-01-06
KR20160104579A (ko) 2016-09-05
CN107635994A (zh) 2018-01-26
KR102577178B1 (ko) 2023-09-11
US20190031669A1 (en) 2019-01-31
MX2017010630A (es) 2017-11-16
IL254070B (en) 2020-07-30
JP6692367B2 (ja) 2020-05-13
US20160251361A1 (en) 2016-09-01

Similar Documents

Publication Publication Date Title
PH12020551315A1 (en) Benzoxazepin oxazolidinone compounds and methods of use
MX2022012317A (es) Oxisteroles y metodos de uso de los mismos.
EA201790024A1 (ru) Модуляторы toll-подобных рецепторов для лечения вич
BR112017003054A2 (pt) compostos de aminopirimidinila como inibidores de jak
PH12018500065A1 (en) Oxysterols and methods of use thereof
EA201891203A1 (ru) Гетероциклические соединения в качестве иммуномодуляторов
EA201891494A1 (ru) Гетероциклические соединения в качестве иммуномодуляторов
PH12018500061A1 (en) Oxysterols and methods of use thereof
EA201791256A1 (ru) Производные хиназолина, применяемые для лечения вич
MX2018009257A (es) Derivados de benzimidazol como moduladores de ror-gamma.
EA201790785A1 (ru) Производные тетрагидроизохинолина
MX2017014375A (es) Moduladores del ccr2.
BR112016030733A2 (pt) Derivados de indano e indolina e uso dos mesmos como ativadores de guanilato ciclase solúveis
EA201700504A1 (ru) 5-ароматическое алкинилзамещенное бензомидное соединение и способ его получения, фармацевтическая композиция и их применение
EA201691600A1 (ru) Дигидропиридиноновые ингибиторы mgat2 для применения в лечении метаболических нарушений
EA201792374A1 (ru) Азабензимидазолы и их применение в качестве модуляторов рецептора ampa
EA201790726A1 (ru) Фармацевтическая композиция для лечения язвенного колита
EA201891377A1 (ru) ПРИМЕНЕНИЕ МОДУЛЯТОРОВ КАНАЛОВ Kv3.1/Kv3.2/Kv3.3 ДЛЯ ЛЕЧЕНИЯ БОЛИ
CU20170158A7 (es) Derivados sustituidos de 1-arilnaftiridina-3-carboxamidas y su utilidad en el tratamiento o prevención de enfermedades cardiovasculares y renales
BR112016026552A8 (pt) derivados de carboxamida, seus usos, composição farmacêutica, e combinação
EA201792594A1 (ru) Положительные аллостерические модуляторы мусаринового рецептора м1
EA201890684A1 (ru) Производные фториндола в качестве положительных аллостерических модуляторов мускаринового рецептора m1
GEP20186893B (en) Pyrazines modulators of gpr6
MX2021000841A (es) Derivados de quinazolinona sustituidos y su uso como moduladores alostericos positivos de mglur4.
MX2017006476A (es) Terapia de combinacion efectiva contra microorganismos, que incluye microorganismos resistentes a farmacos.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 25/02/2016, OBSERVADAS AS CONDICOES LEGAIS